

Serial No. 10/679,746

Remarks


The Examiner has determined that independent Claims 23, 35, and 47 are directed to patentably distinct species, namely pioglitazone and rosiglitazone. Applicant elects pioglitazone for initial examination with traverse.

All independent claims read on the elected species. All dependent claims read on the elected species except claims 27 and 39.

Applicants respectfully disagree with the Examiner in that the inventions are distinct. Applicants have discovered that co-administration of a GLP-1 peptide agonist along with pioglitazone and rosiglitazone unexpectedly enhance glycemic control while avoiding heart hypertrophy that can occur when pioglitazone or rosiglitazone are administered alone. (See page 8 of the specification.)

If, for any reason, the Examiner feels that a telephone conversation would be helpful in expediting the prosecution of this case, the Examiner is urged to call me.

Respectfully submitted,



Gregory A. Cox  
Attorney for Applicants  
Registration No. 47504  
Phone: 317-277-2620

Eli Lilly and Company  
Patent Division/GAC  
Lilly Corporate Center  
Indianapolis, Indiana 46285

March 31, 2006